Private Label Tranexamic Acid SPF 50 Serum Manufacturer

The minimum order quantity for a private label tranexamic acid SPF 50 serum typically starts at 500 units among small-batch, indie-friendly contract manufacturers, though 1,000 units is more common when SPF in-vivo testing and OTC drug compliance are factored in. Larger, pharmaceutical-grade sunscreen manufacturers usually enforce MOQs of 5,000–10,000 units because the regulatory overhead of an FDA OTC monograph product — facility registration, drug-facts labeling, SPF efficacy testing — spreads fixed costs across volume. Several variables push MOQ up or down. A stock or semi-custom base formula (where the manufacturer already has a validated SPF 50 serum platform and you're layering in tranexamic acid at a tested, compatible percentage) will often allow a lower MOQ because development risk is reduced. A fully bespoke formula built from scratch with novel UV filter combinations and a high tranexamic acid load (4–5%) requires more development investment, and manufacturers offset that by requiring larger minimum runs. Fill format matters too. Airless pumps are mechanically more demanding to fill at low volumes than straight-neck tubes or disc-top bottles, so airless configurations sometimes carry a MOQ premium of 20–30% above the base. Similarly, if you want secondary packaging — a printed carton with drug-facts compliance copy — the carton printer's MOQ (often 1,000 units minimum) may become the binding constraint rather than the fill itself. Geography also plays a role. US-based manufacturers operating under FDA OTC drug registration tend to have higher MOQs than Korean or European co-manufacturers, where sunscreens are regulated as cosmetics and the compliance burden is lighter. Korean OEM labs, in particular, are well known for SPF 50 serum expertise and will sometimes run 300–500-unit pilots for established indie brands with a credible purchase history. The best tactic for a first-time founder is to request a pilot or development run at a slightly lower volume (300–500 units) at a premium cost per unit, with a written commitment to a follow-on full run at a negotiated price once the formula is market-validated. Many manufacturers will honor this structure if you present a coherent brief and demonstrate regulatory awareness. Platforms like AJ Cosmo Labs let you filter manufacturers directly by disclosed MOQ thresholds, so you're not spending weeks emailing labs only to discover their minimum is ten times your budget. Post your brief on the AJ Cosmo Labs app and filter for cosmetic contract manufacturers who have SPF OTC capability and a stated MOQ at or below your target.

From the day you lock a formulation brief with your contract manufacturer to the day finished goods ship, expect 10–16 weeks for a private label tranexamic acid SPF 50 serum. That range is not arbitrary — it maps directly to the sequential process steps involved in making an OTC drug-cosmetic hybrid, and compressing any one step carries real regulatory and quality risk. Weeks 1–3 cover formula development. If you're customizing a stock SPF 50 base by incorporating tranexamic acid at 2–5%, development is faster — some manufacturers deliver a prototype in 1–2 weeks. A fully bespoke formula with a novel UV filter system can take 3–4 weeks to reach a stable prototype. Weeks 3–6 cover in-house or lab-partner stability screening. A preliminary 28-day accelerated stability test (40°C/75% RH) is usually run before SPF testing to confirm the formula doesn't separate, discolor, or degrade under stress. If it fails, you go back to the bench, which adds 2–3 weeks. Weeks 6–10 cover SPF efficacy testing. In-vivo SPF testing per ISO 24444 (required for most US and EU market claims) is conducted on human subjects at a certified testing lab. Booking alone can take 2–3 weeks, and results take another 2–3 weeks. In-vitro testing (faster, cheaper, but not accepted for US OTC drug claims) can cut this to 1–2 weeks if you're launching only in markets that accept it. Weeks 10–13 cover regulatory review, label copy finalization (Drug Facts panel for the US, INCI labeling for the EU), and artwork sign-off. First-time brands consistently underestimate this step — a Drug Facts panel has strict FDA-mandated formatting requirements, and any revision resets the printer queue. Weeks 13–16 cover production scheduling, bulk manufacture, fill-and-finish, and quality-control release testing (microbial limits, viscosity, pH, SPF verification on production batch). Add 1–2 weeks for freight if the manufacturer is overseas. The most common reason timelines slip beyond 16 weeks is late art approval or a stability failure requiring reformulation. Submit your packaging artwork to the printer and your label copy to a regulatory consultant in parallel with SPF testing, not after. AJ Cosmo Labs connects you with manufacturers who provide milestone timelines upfront so you can plan your launch calendar before the first deposit clears.

The most-cited efficacy concentration for tranexamic acid in topical cosmetic formulas is 2–5%, with 3% being the threshold at which the majority of published peer-reviewed studies demonstrate statistically significant improvement in melasma and post-inflammatory hyperpigmentation scores compared to placebo. A 2% concentration is considered the practical minimum for consumer perception of efficacy, while concentrations above 5% are rarely formulated because they don't demonstrably outperform 3–5% in dermatologist-graded clinical outcomes and add unnecessary raw material cost. For an SPF 50 serum specifically, the formulation challenge is that tranexamic acid is water-soluble and must be incorporated into the aqueous phase, while many high-performance UV filters are oil-soluble and sit in the emollient phase. A skilled cosmetic chemist needs to balance the water activity in the aqueous phase — where TXA dissolves — against the emulsion stability required to keep an SPF 50 system homogenous over a two-year shelf life. At concentrations above 4%, tranexamic acid can influence the ionic environment of the emulsion and affect the efficacy of certain chemical UV filters, particularly those sensitive to pH shifts. Mineral SPF systems (zinc oxide, titanium dioxide) are generally more tolerant of high TXA concentrations because they are inorganic particulates rather than UV-reactive molecules. If you're planning a clean-beauty or sensitive-skin positioning for your serum, a mineral-filter base at 3–4% TXA is a well-validated starting point that your contract manufacturer can often adapt from an existing platform formula. From a regulatory standpoint, tranexamic acid is classified as a cosmetic active in the US, EU, and most APAC markets at these concentrations — it does not trigger drug classification on its own. The SPF 50 claim is what triggers OTC drug status in the US. Your INCI declaration must list tranexamic acid by its correct INCI name (tranexamic acid), and your concentration should be verifiable by HPLC assay during quality-control release testing. When briefing manufacturers through the AJ Cosmo Labs app, specify your target tranexamic acid percentage in the brief — it helps cosmetic chemists on the platform immediately assess whether your spec is compatible with their existing SPF 50 base platforms, saving weeks of back-and-forth.

For a private label tranexamic acid SPF 50 serum, the single most important credential is FDA facility registration for OTC drug manufacturing. In the United States, any product bearing an SPF claim is regulated as an OTC drug under 21 CFR Part 352, meaning the manufacturing facility must be registered with the FDA and operate under current Good Manufacturing Practice (cGMP) standards defined in 21 CFR Parts 210 and 211. Ask prospective manufacturers for their FDA registration number and verify it directly in the FDA's establishment registration database — this is publicly searchable. ISO 22716:2007 (Good Manufacturing Practices for Cosmetics) is a useful secondary credential that indicates quality-system rigor, but it does not substitute for FDA OTC drug registration if you're selling in the US. Many Korean and European co-manufacturers hold ISO 22716 without FDA registration, which means they can manufacture your formula for non-US markets but cannot legally produce it for US retail as an OTC drug. For SPF efficacy, the testing lab (which may be the manufacturer's in-house lab or a contracted CRO) should be accredited to ISO 24444 for in-vivo SPF testing and ISO 24442 for UVA protection factor testing. Some markets, including the EU, additionally require a UVA PF that is at least one-third of the labeled SPF — for an SPF 50 product, that means a minimum UVA PF of 16.7. Verify that the testing partner can provide both reports. If your brand positions around clean beauty or natural cosmetics, look for manufacturers with Ecocert or COSMOS certification, or at minimum a demonstrated ability to formulate with EWG-verified UV filter systems. These certifications are not legally required but are often demanded by retailers like Whole Foods, Credo, or Follain. For EU market entry, your manufacturer or a designated EU Responsible Person must complete a Cosmetic Product Safety Report (CPSR) and submit a CPNP notification before the product reaches market. Post-Brexit, a separate UK Responsible Person and SCPN notification are required for Great Britain sales. AJ Cosmo Labs pre-screens manufacturers on the platform for their disclosed certifications and regulatory capabilities, so when you filter for SPF-capable contract manufacturers, you're already looking at suppliers who have indicated their compliance credentials.

Total development costs for a private label tranexamic acid SPF 50 serum at a low-MOQ run (500–1,000 units) typically fall between $8,000 and $22,000 before you account for cost of goods on the production units themselves. That wide range reflects real differences in formula complexity, SPF testing pathway, and packaging choices — not padding. Formulation development fees range from $1,500 to $5,000. At the low end, you're adapting a manufacturer's stock SPF 50 base to incorporate tranexamic acid at a pre-validated percentage. At the high end, you're commissioning a fully custom formula with a specific UV filter architecture, a targeted skin feel, and additional actives (niacinamide, kojic acid, vitamin C) that need compatibility testing alongside the TXA and the SPF system. SPF efficacy testing is one of the largest line items. In-vivo testing per ISO 24444 at a certified CRO costs $3,000–$8,000 depending on the number of subject panels and whether UVA PF testing is included. In-vitro testing is faster and cheaper ($500–$2,000) but is not accepted for US OTC drug label claims — it's only viable if you're launching exclusively in markets that accept computational or in-vitro methods. Stability testing adds $800–$2,500 for a standard accelerated (3-month, 40°C/75% RH) plus real-time study. Most retail buyers and dermatologist partners will request stability data before stocking your product, so this is not optional. Cost of goods on the finished units — bulk manufacture, fill-and-finish, packaging materials, and labeling — runs $4.50–$9.00 per unit at 500–1,000 unit volumes. UV filter cost is the single largest ingredient driver: non-nano zinc oxide at high load is expensive, while chemical-filter systems are often cheaper per kilogram but require more complex formulation expertise. At 1,000 units and $7/unit COGS, your production cost alone is $7,000. Label and regulatory review — drafting and proofing the Drug Facts panel, INCI list, and net weight — adds $500–$2,000 depending on whether you use the manufacturer's in-house regulatory team or an independent cosmetic regulatory consultant. To summarize: budget $12,000–$20,000 as a realistic all-in development and first-run cost for a 500–1,000 unit launch of a TXA SPF 50 serum in the US market. Brands often recoup this in one or two sell-through cycles at a $45–$75 retail price point with a 4–5x markup on COGS. Use the AJ Cosmo Labs app to get itemized quotes from multiple manufacturers so you can benchmark each component before committing.

Selling a single tranexamic acid SPF 50 serum formula in both the US and EU is possible but requires careful UV filter selection from the outset, because the two regulatory frameworks maintain different approved filter lists. The US FDA OTC sunscreen monograph permits a specific set of UV filters — including zinc oxide, titanium dioxide, avobenzone, octinoxate, octisalate, octocrylene, and a handful of others — while the EU's Cosmetics Regulation (EC) 1223/2009 Annex VI permits a broader list that includes advanced filters like tinosorb S (bis-ethylhexyloxyphenol methoxyphenyl triazine), tinosorb M, mexoryl SX, and mexoryl XL. The practical implication: if you build your SPF 50 formula using tinosorb S or mexoryl SX for a photostable, cosmetically elegant finish, that formula cannot be sold in the US as an OTC drug because those filters are not FDA-approved. Conversely, a formula relying heavily on avobenzone (US-approved) may require additional photostabilizers in the EU context, though avobenzone is EU-approved so it's a workable ingredient in both markets. The most viable dual-market approach is to formulate with a UV filter system drawn exclusively from the intersection of both approved lists: zinc oxide, titanium dioxide, avobenzone (combined with octocrylene or a photostabilizer), and octisalate. Many Korean OEM labs are highly experienced in building dual-compliant SPF 50 systems for brands that want global launch capability, and they often already have validated base platforms on file. Beyond the formula, the labeling requirements diverge significantly. The US requires a Drug Facts panel with specific FDA-mandated formatting, active ingredient declaration by percentage, and defined warnings. The EU requires a standard cosmetic label with INCI nomenclature, a responsible person declaration, CPNP notification, and a Cosmetic Product Safety Report signed by a qualified safety assessor. These are two completely different label layouts — you will need market-specific packaging artwork even with a shared formula. For UK sales post-Brexit, add a third layer: a separate UK Responsible Person, a UK Product Notification through the Office for Product Safety and Standards (OPSS), and a UK CPSR. The formula itself can be the same as the EU version if it's dual-compliant, but all documentation and labeling must be UK-specific. Tranexamic acid itself is not restricted in any of these markets at 2–5% concentrations — it is classified as a cosmetic active universally at those levels. The SPF 50 claim is the regulatory complexity driver. Work with a manufacturer who has regulatory experience in at least two of these three markets, and engage a regulatory consultant to review your label copy before printing. AJ Cosmo Labs lists manufacturers' declared regulatory market experience so you can shortlist those with US and EU SPF track records before your first conversation.

Finding a vetted, low-MOQ cosmetic contract manufacturer capable of producing an SPF 50 serum with tranexamic acid is genuinely harder than sourcing a manufacturer for a non-SPF cosmetic, because the OTC drug regulatory overlay filters out most generalist labs. The following process gives you the best shot at landing a qualified partner without wasting months on dead ends. Start with a written brief before you contact anyone. Your brief should specify: target tranexamic acid percentage, desired UV filter philosophy (mineral, chemical, or hybrid), fill volume and format (30 mL airless pump is the most common for a serum), target MOQ and budget per unit, target launch markets (US, EU, or both), and any additional actives or skin-feel requirements. A manufacturer receiving a detailed brief will give you a faster and more accurate quote than one receiving a vague inquiry. Vet for FDA facility registration first. Request the manufacturer's FDA establishment registration number and cross-reference it on the FDA's public database. Any US-market SPF manufacturer unable to provide this should be eliminated immediately. For overseas manufacturers supplying the US, they must also be registered or export to a US-based registered facility that handles domestic fill-and-finish. Ask for an SPF-specific reference. Request the name and approximate SKU of a comparable SPF 50 serum or fluid they have manufactured in the last 24 months. A credible manufacturer will share this without hesitation. If they hedge, it often means SPF is not core to their capabilities and they are pitching for your business speculatively. Request a sample of an existing SPF 50 serum from their portfolio before signing a development agreement. Evaluate it for skin feel, white-cast level, absorption rate, and overall texture quality. A manufacturer who makes excellent SPF products will have samples available; one who struggles with SPF will delay or decline. Negotiate a pilot run structure. For a first launch, ask if the manufacturer will produce a 300–500 unit pilot at a premium cost-per-unit with a contractual right of first refusal on the subsequent full production run at a negotiated rate. Many small-batch labs will accept this for brands that present credibly. AJ Cosmo Labs removes the cold-outreach step entirely. Download the app, post your tranexamic acid SPF 50 serum brief with your MOQ, target market, and formula preferences, and receive responses from pre-screened cosmetic chemists and contract manufacturers who have already disclosed their OTC/SPF capabilities. You can filter by MOQ, geography, and certification before the first message is sent, and manage sample tracking and milestone payments in escrow inside the same app.